Emerging role of carfilzomib in treatment of relapsed and refractory lymphoid neoplasms and multiple myeloma
Proteasome inhibition forms the cornerstone of antimyeloma therapy. The first-in-class proteasome inhibitor, bortezomib, either alone or in combination with other chemotherapeutic agents, induces high overall response rates and response qualities in patients with clinically and molecularly defined h...
| Main Authors: | , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Dove Medical Press
2011
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3102580/ |